Fujirebio is global R&D-driven company constantly developing new IVD testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and ...

Ixico said it was contracted by Fujirebio Diagnostics Inc, a Tokyo-based biomarker research company, to assist with the development of a new blood-based test for Alzheimer's disease called Lumipulse.

Fujirebio, a leading innovator in in-vitro diagnostics, announced a collaboration with Stanford Medicine to advance research and innovation in the field of infectious disease testing. This ...

Fujirebio offers a comprehensive line-up of manual and fully automated assays for neurological diseases and consistently partners with organizations and clinical experts across the world to ...

Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio offers a comprehensive line-up of manual and fully automated assays for ...

Fujirebio's diagnostic assays and biomarkers play a critical role in advancing clinical and translational research. By integrating Bioz Image Badges, Fujirebio can now extract and showcase product ...

Fujirebio's diagnostic assays and biomarkers play a critical role in advancing clinical and translational research. By integrating Bioz Image Badges, Fujirebio can now extract and showcase product ...

Fujirebio Diagnostics Inc.’s Alzheimer’s disease assay received the U.S. FDA’s first clearance for a blood test for the debilitating neurodegenerative disease. Fujirebio’s Lumipulse G ...